Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foundation Hubrecht Organoid Technology

www.hub4organoids.nl

Latest From Foundation Hubrecht Organoid Technology

Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace

J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.

BioPharmaceutical Deals

Despite Vertex's Early Start, Competition Looms In CF

Despite robust launch as expected, analyst anticipates some patients will exit Orkambi therapy due to lack of efficacy or noticeable symptom relief. Meanwhile, companies including Concert and Galapagos are positioning themselves to compete with CFTR-modulating therapies.

BioPharmaceutical Business Strategies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register